Across TCGA pan-cancer cohorts, HLA-F Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HLA-F data layer compared with 21 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher HLA-F Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HLA-F expression acts as an unfavorable survival marker.
LIHC, ESCA, and SKCM are the cancer types where HLA-F Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.